Research On The Innovation And Development Strategy Of China’s Biomedical Industry

The report of the 19 th National Party Congress pointed out: "Innovation is the first driving force for leading development.We must aim at the forefront of science and technology in the world and achieve major breakthroughs in leading original results.In China’s "Eleventh Five-Year Plan","Twelfth Five-Year Plan" and "Thirteenth FiveYear Plan",China clearly stated that it is necessary to speed up the development of the biomedical industry,and during the "Thirteenth Five-Year Plan" period,It establishes the goal of establishing a relatively complete biomedical innovation system.At present,there are still many deficiencies in the research on the development of biomedical industry in China.Most scholars focus on the path of innovation and development of biomedical industry mainly in the following aspects: policy guidance;market concentration;industrial agglomeration;the development model of combining production,learning and research,etc.,ignoring the innovation environment and structure of industrial development.The fundamental path and Countermeasures for the development of China’s biomedical industry have not yet been found in theory.With the regulatory system and intellectual property protection system as the main content,the importance of building an innovative guarantee system for the development of biomedical industry is clarified.Secondly,it is proposed to build an innovative development system of biomedical industry,which integrates medicine,industry,education and research,with the government as the leading factor.On the basis of emphasizing the establishment of good mechanism by enterprises and scientific research institutions,the important role of government and medical institutions in the development of biomedical industry is emphasized.The development of biopharmaceutical industry can not be separated from the government’s policy guidance and industry supervision.As the clinical trial base of bio-medicine and the main consumer market of bio-pharmaceutical products,the role of government and medical institutions in the development of bio-pharmaceutical industry can not be ignored.On the basis of reading Chinese and foreign literature,this paper studies the current situation and problems of China’s biomedical industry,clarifies the theoretical and practical significance of the topic,and through case studies and empirical analysis,deeply excavates the important factors affecting the development of biomedical industry and the guarantee basis.On this basis,it explores the innovative development strategy of biomedical industry,which is led by the government and integrates medicine,production,education and research.The main contents are composed of the following seven parts:Firstly,the basic connotation and main objectives of innovation and development of biomedical industry are clarified in theory.On the basis of supply-side reform theory,industrial structure optimization theory,innovation theory and strategic emerging industry theory,combining with the background,connotation and significance of supply-side reform in China,this paper analyzed the direction and goal of the development of biomedical industry in China;the development of Western supply theory,including Say’s law and Keynes’ s law Doctrine,supply school and supply management theory;in the theory of industrial structure optimization,it focuses on the rationalization and upgrading of industrial structure;in the theory of innovation,it explores the essence of the theory of technological innovation and institutional innovation;and in the theory of strategic emerging industries,it mainly discusses the new strategy.The development field and trend of industrial development.Secondly,the relationship between supply-side reform theory,industrial structure optimization theory,innovation theory and strategic emerging industry theory and biomedical industry development is analyzed.Secondly,the current situation and problems of the development of biomedical industry in China are analyzed through comparison between China and foreign countries.Firstly,the related concepts of biomedical industry are defined;secondly,the development status and characteristics of biomedical industry in China are introduced,the particularity of biomedical industry is analyzed,the development of biomedical industry in China is studied,and compared with that of Foreign Biomedical industry.From four aspects of government policy,medical institutions,enterprises and scientific research,this paper summarizes the problems existing in the development of biomedical industry in China.Thirdly,the main factors of innovation and development of China’s biomedical industry are analyzed.The main factors affecting the innovation and development of biomedical industry are analyzed from the aspects of government,medical institutions,enterprises,universities and scientific research institutions.From the perspective of the government,the impact of government policies on the innovation and development of biomedical industry is analyzed from four aspects: regulatory system,drug pricing,ethical review and intellectual property rights.From the perspective of medical institutions,the impact of medical institutions on the innovation and development of biomedical industry is analyzed from three aspects: limited clinical trial resources,data fraud and unclear institutional positioning.The impact of innovation and development of bio-pharmaceutical industry;from the perspective of enterprises,the impact of enterprises on innovation and development of bio-pharmaceutical industry is analyzed from three aspects: concentration of Bio-pharmaceutical enterprises and original innovation,production-university-research alliance.From the perspective of universities and scientific research institutions,the impact on innovation and development of biomedical industry is due to the shortage of comprehensive high-quality talents and the low conversion rate of scientific research achievements.Fourthly,empirical analysis is made on the influencing factors of innovation and development of China’s biomedical industry.Based on the four influencing factors of government,medical institutions,enterprises,universities and scientific research institutions,this paper makes an empirical analysis by using VAR model.From the perspective of government policy,the main indicators are government investment funds and sales revenue of new products in interest tax and fund raising of scientific research activities.The empirical results show that the impact of interest tax on sales revenue of new products is relatively large.From the perspective of medical institutions,new product development expenditure and new product sales revenue are selected as the main analysis variables,and new product development expenditure has a significant impact on new product sales revenue.Regarding enterprises,this paper analyses the influence of input of different factors of production on the output of bio-medicine.It concludes that the internal expenditure of R&D funds and the full-time equivalent of R&D personnel influence the output of bio-medicine manufacturing industry from four aspects: land,capital,technology and labor.The impact of input on the output of biopharmaceutical manufacturing industry is relatively small.Regarding universities and scientific research institutions,the number of effective invention patents and sales revenue of new products are selected as the main indicators.In the transformation stage of biomedical achievements,the number of effective patents plays a role in promoting sales revenue of new products,and the degree of impact shows an increasing trend.Fifth,the paper refer to the development model and case analysis of Foreign Biomedical industry.From the perspective of government and enterprises,the paper analyses the development models of biomedical industry in the United States,Japan and India,and finds that the United States,Japan and India promulgate different industrial policies to promote the development of biomedical industry at different stages of development.Taking three companies as examples,this paper explores the development path of three typical Biopharmaceutical Enterprises under the guidance of industrial policy.Companies of the United States and Japan paid attention to the research and development of new products in the early stage,and launched "blockbuster" level new drugs one after another to help them occupy a certain market share;after a certain stage of scale development.They mainly acquired the patent of new products through mergers and acquisitions at home and abroad,and at the same time expanded.It has broadened its own sales channels and formed a complete industrial chain of R&D,production and sales.The early development of company in India mainly focused on the development and production of generic drugs.With the expansion of market scale and the enhancement of R&D capability,it began to turn to the research and development of innovative drugs.Analyzing the difference between United States,Japan,India and China means a lot to the development of biomedical industry in China.First of all,the government need to improve the relevant industrial policies,such as the construction of intellectual property system and supervision system.Secondly,enterprises should pay attention to research and development of biomedical products and emphasize the role of technological innovation because of the similarity with Indian.Sixth,we should build an innovative guarantee system for the development of biomedical industry.Emphasizing the necessity of building industrial security system,building the overall framework of the security system,with the supervision system and intellectual property protection system as the main content,focusing on the construction of the security system ideas.From the aspect of supervision system,this paper studies the current situation and main defects of the supervision of biomedical industry in China,and puts forward the significance of constructing the supervision system of biomedical industry.From the aspect of intellectual property protection system,this paper studies the current situation of intellectual property protection at home and abroad,analyses the current situation and problems of the construction of intellectual property system in China,and puts forward some suggestions to improve the intellectual property protection system in China.Seventh,we should build a government-led innovation system in medicine,production,education and research.On the basis of the previous research,this paper puts forward the general idea of building a government-led innovation system of medicine,production,education and research,and puts forward the specific contents of the government-led innovation system of technology,policy and market.To build a government-led innovation system of medicine,industry,education and research,we need to take the government as the core,proceed from the four perspectives of medicine,industry,education and research,take technological innovation,policy innovation and market innovation as three paths,and take financing,research and development,clinical trials and market investment as four entry points to analyze the problems in depth.The system proposes solutions.